MARKET

CDTX

CDTX

Cidara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.010
-0.010
-0.50%
After Hours: 2.010 0 0.00% 16:00 05/14 EDT
OPEN
2.050
PREV CLOSE
2.020
HIGH
2.050
LOW
1.980
VOLUME
286.99K
TURNOVER
--
52 WEEK HIGH
4.450
52 WEEK LOW
1.760
MARKET CAP
97.06M
P/E (TTM)
-1.1156
1D
5D
1M
3M
1Y
5Y
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com · 2d ago
Cidara Therapeutics Q1 EPS $(0.39) Up From $(0.46) YoY, Sales $2.40M Down From $2.53M YoY
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(0.39) per share. This is a 15.22 percent increase over losses of $(0.46) per share from the same period last year. The company reported $2.40 million in
Benzinga · 2d ago
Cidara Therapeutics EPS misses by $0.05, misses on revenue
Cidara Therapeutics (CDTX): Q1 GAAP EPS of -$0.39 misses by $0.05.Revenue of $2.41M (-4.7% Y/Y) misses by $5.47M.Shares -0.5% AH.Press Release
Seekingalpha · 2d ago
BRIEF-Cidara Provides Corporate Update And Reports First Quarter 2021 Financial Results
reuters.com · 2d ago
-- Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $2.4M
MT Newswires · 2d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 3d ago
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 4d ago
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 05/05 20:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDTX. Analyze the recent business situations of Cidara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDTX stock price target is 6.67 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 25.46M
% Owned: 52.72%
Shares Outstanding: 48.29M
TypeInstitutionsShares
Increased
11
558.03K
New
4
53.28K
Decreased
13
931.50K
Sold Out
6
2.89M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Independent Director
Daniel Burgess
President/Chief Executive Officer/Director
Jeffrey Stein
Chief Financial Officer
James Levine
Chief Operating Officer
Paul Daruwala
Executive Vice President
Christopher Kurtz
General Counsel/Secretary
Jessica Oien
Other
Neil Abdollahian
Other
Taylor Sandison
Director
Canale-Theakston ..
Director
Bonnie Bassler
Independent Director
Timothy Franson
Independent Director
David Gollaher
Independent Director
Chrysa Mineo
Independent Director
Theodore Schroeder
No Data
  • All
  • Financials
  • Insiders
More
About CDTX
Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.